Palisade Bio, Inc.

Healthcare · Biotechnology · United States

Last price 1.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 207.38M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and co...